Pharma Focus Asia

Boehringer Ingelheim Begins US$99 million New Tablet Production Facility

Introduction:

Boehringer Ingelheim had begun construction of a new production facility for innovative drugs with an investment of US$99 million.

Features:

The new production facility will focus on the development activities for drugs in tablet form and manufacture them across the globe.

The facility will be capable for modern and flexible production and also helps to market new, innovative drugs.

It will be started in 2020 and 75 employees will develop new production methods for tablet preparations.

The new tablet production facility will continue to manufacture drugs that require highly complex production technologies.

The production facility is expected to operational by 2022.

Specifications:

NameBoehringer Ingelheim
BudgetUS$99 Million
LocationGermany
TypeExpansion
ScheduleTo be operational by 2022
magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024